about
The perils of PCR: can we accurately 'correct' antimalarial trials?A randomized open-label trial of artesunate- sulfadoxine-pyrimethamine with or without primaquine for elimination of sub-microscopic P. falciparum parasitaemia and gametocyte carriage in eastern SudanDynamics of pfcrt alleles CVMNK and CVIET in chloroquine-treated Sudanese patients infected with Plasmodium falciparum.Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.Global and local genetic diversity at two microsatellite loci in Plasmodium vivax parasites from Asia, Africa and South America.Directional selection at the pfmdr1, pfcrt, pfubp1, and pfap2mu loci of Plasmodium falciparum in Kenyan children treated with ACT.Prevalence of Plasmodium falciparum anti-malarial resistance-associated polymorphisms in pfcrt, pfmdr1 and pfnhe1 in Muheza, Tanzania, prior to introduction of artemisinin combination therapy.Increased pfmdr1 copy number and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients treated with artemether-lumefantrine.A comparative study on the efficacy of artesunate plus sulphadoxine/pyrimethamine versus artemether-lumefantrine in eastern Sudan.Epidemiology of subpatent Plasmodium falciparum infection: implications for detection of hotspots with imperfect diagnostics.Selection of pfdhfr/pfdhps alleles and declining artesunate/sulphadoxine-pyrimethamine efficacy against Plasmodium falciparum eight years after deployment in eastern Sudan.Culture-adapted Plasmodium falciparum isolates from UK travellers: in vitro drug sensitivity, clonality and drug resistance markers.Hot spot or not: a comparison of spatial statistical methods to predict prospective malaria infections.The polymorphic linker domain of pfmdr1 is associated with resistance-conferring mutations in Plasmodium falciparum populations from East and West Africa.Chloroquine-resistant Plasmodium falciparum infections among UK travellers returning with malaria after chloroquine prophylaxis.
P50
Q24615919-9ACE96AF-AA23-4EFF-8B2C-E585D3D236C3Q28471717-AA5ABB2C-A644-4C49-90B9-30B6E6F11C48Q33763957-38573AAE-FA98-41E7-9F92-97BE4F602549Q34281680-2A063E75-DBCA-4D89-A873-BC316F5E8C02Q34354870-0F4F6DEC-87DB-42CB-84F2-23EAEA29BAB4Q34563560-5D739912-A5EA-4C0A-B12A-2EC72075C17EQ35356543-129E189A-89FD-42D3-87A2-357B1462E9FCQ35364589-64FEC189-A104-43FF-AF48-18F6CD19C127Q35925276-F8CF2ECF-40F5-494F-8C7F-BEBAE257F53FQ36982630-B5031600-A60E-4715-AEFD-6344CA2E6774Q37038288-3B1E1E6B-41DC-486F-BAF7-A31AA96403F0Q37357025-9C17D276-96B1-4722-821A-ADD4B48BF042Q37598139-B1E1D5E6-C69A-4B9E-B113-F354AB5594CFQ39320463-D62FB291-4FFF-4896-A668-80DDA2C1B02CQ39500151-9F2667A0-4D49-4EAB-B97C-2627A3EFC391
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nahla Gadalla
@ast
Nahla Gadalla
@en
Nahla Gadalla
@es
Nahla Gadalla
@nl
Nahla Gadalla
@sl
type
label
Nahla Gadalla
@ast
Nahla Gadalla
@en
Nahla Gadalla
@es
Nahla Gadalla
@nl
Nahla Gadalla
@sl
prefLabel
Nahla Gadalla
@ast
Nahla Gadalla
@en
Nahla Gadalla
@es
Nahla Gadalla
@nl
Nahla Gadalla
@sl
P106
P1153
18436379700
P31
P496
0000-0002-6177-6705